After a breast cancer diagnosis, one of the hardest questions is whether it will come back.

@SimBioSys is helping doctors and patients better understand that risk. Powered by NVIDIA technology, its FDA-cleared TumorSight Risk analyzes an existing breast MRI alongside pathology and clinical information to estimate the risk of cancer returning at five and ten years.

For women with HR-positive, HER2-negative early-stage breast cancer, those insights can be available before surgery, giving them and their doctors more information as they talk through treatment options.

AI can help give patients and their doctors more information when the decisions ahead feel most difficult.